Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Assembly Biosciences Inc | ASMB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 15.16 | 05:19:36 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 15.16 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 7.692 - 20.04 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 15.16 | USD |
Assembly Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 83.12M | 5.48M | - | 7.16M | -61.23M | -11.17 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Assembly Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ASMB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.64 | 16.27 | 14.68 | 15.35 | 17,950 | -0.48 | -3.07% |
| 1 Month | 14.65 | 16.45 | 14.28 | 15.12 | 14,884 | 0.51 | 3.48% |
| 3 Months | 13.35 | 16.45 | 12.00 | 13.98 | 18,006 | 1.81 | 13.56% |
| 6 Months | 9.24 | 16.45 | 8.8188 | 11.09 | 141,285 | 5.92 | 64.07% |
| 1 Year | 12.96 | 20.04 | 7.692 | 12.90 | 589,977 | 2.20 | 16.98% |
| 3 Years | 49.92 | 50.16 | 7.692 | 23.50 | 537,330 | -34.76 | -69.63% |
| 5 Years | 180.84 | 348.00 | 7.692 | 64.32 | 576,486 | -165.68 | -91.62% |
Assembly Biosciences Description
| Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program. |
